SAN FRANCISCO, October 4, 2016 /PRNewswire/ --
The biological safety testing market is expected to reach USD 5.54 billion by 2024, according to a new report by Grand View Research, Inc. The biological safety testing market is primarily driven by exponential growth in the production of biologics and medical devices that demand stringent safety requirements. The growing disease burden is anticipated to be the major cause for high production of biologics, thus contributing towards market growth.
(Logo: http://photos.prnewswire.com/prnh/20150105/723757 )
The overwhelming adoption rate of unhealthy lifestyles has resulted in the high prevalence of chronic diseases, such as cancer and diabetes, which is serving as a key contributing factor toward increasing drug development and their subsequent commercialization. This is presumed to raise the need to scrutinize and ensure the safety of targeted and specialized therapies, evaluate their outcomes, and circumvent probable shortcomings.
As a consequence of the high manufacturing intensity, pharmaceutical and biotechnology companies are increasingly incorporating biological safety testing tools to produce highly potent and contamination-free biologics to cater to the large population suffering from target diseases.
In addition, stringent regulations issued by healthcare organizations globally are presumed to be responsible for the high uptake of biological safety testing tools, thus resulting in a wider scope for the biological safety testing market
For instance, the European Medical Device Directives are believed to have a higher influence on the implementation of the defined imperative regulations to meet the growing safety requirements, thus translating into improved biological safety and contributing to overall growth of this vertical.
Browse full research report with TOC on "Biological Safety Testing Market Analysis By Product (Reagents & Kits, Instruments, Services), By Application (Stem Cell, Tissue & Tissue-Based Products, Gene Therapy, Blood & Blood-Based Products, Vaccines & Therapeutics), By Test (Sterility Tests, Cell Line Authentication & Characterization Tests, Bioburden Tests, Endotoxin Tests, Adventitious Agent Detection Tests, Residual Host Contamination Detection Tests), And Segment Forecasts To 2024" at: http://www.grandviewresearch.com/industry-analysis/biological-safety-testing-market
Further Key Findings From the Study Suggest:
Grand View Research has segmented the biological safety testing market on the basis of product, application, test, and region:
Browse related reports by Grand View Research:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Read Our Blogs - legalworkshop.org, grandviewresearch.com/blogs/healthcare
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Share this article